OakChart

Generate Biomedicines Inc

GENBHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

13.49-0.29 (-2.10%)
2026-11-12 00:01 CET
Market cap
1,768.69 USD m
Revenue, TTM
6.31 USD m
Net income, TTM
-67.25 USD m
Free cash flow, TTM
-58.88 USD m
EPS diluted, TTM
-0.52
P/E
-
Compare

Price

GENB against its 20 and 50-day averages
2050earnings
12.5015.0017.5020.0022.502.3M4.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GENBclose 13.4920-day 13.4250-day 14.5113.4952w high

40.5% under the 52-week high of 22.67 on 25 Aug 2026. 52-week low 11.00 on 4 Mar 2026. Last 15 sessions, 34.9% high to low

Volume 0.38× normal · the line is the 50-bar volume average

Profile

GENB
52-week range, 21% of the way up
11.0022.67

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

IndexRUT
Employees312
IPOFeb 27, 2026
ATR, 14d1.04
Rel volume0.38
Short float16.45%
Insider own56.98%
Inst own26.66%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.73B
Enterprise Value1.34B
Income-
Sales-
Book/sh3.56
Cash/sh3.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees312
IPOFeb 27, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.79
P/C3.79
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.30
Current Ratio8.30
Debt/Eq0.14
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-2.29
EPS next Q-0.56
EPS this Y49.87%
EPS next Y-0.73%
EPS next 5Y26.80%
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsAug 06 BMO
EPS/Sales Surpr.-2.30% 19.13%

Ownership

Insider Own56.98%
Insider Trans-0.02%
Inst Own26.66%
Inst Trans10.12%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.53%
SMA50-7.05%
SMA200-3.96%
Trades-

Technical

Shs Outstand128.27M
Shs Float55.21M
Short Float16.45%
Short Ratio7.57
Short Interest9.08M
52W High22.67 -40.49%
52W Low11.00 22.64%
Volatility8.90% 8.00%
ATR (14)1.04
RSI (14)48.26
Beta-
Rel Volume0.38
Avg Volume1.20M
Volume452,755

Performance

Perf Week-4.73%
Perf Month10.08%
Perf Quarter-10.25%
Perf Half Y-16.83%
Perf YTD-10.07%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price27.00
Prev Close13.78
Price13.49
Change %-2.10%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Apr 13, 2026InitiatedHH.C. WainwrightBuy$16+18.6%
Mar 24, 2026InitiatedPPiper SandlerOverweight$24+77.9%
Mar 24, 2026InitiatedMMorgan StanleyOverweight$20+48.3%
Mar 24, 2026InitiatedGGuggenheimBuy$30+122.4%
Mar 24, 2026InitiatedGGoldmanBuy$26+92.7%
Mar 24, 2026InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
ABSIAbsci Corp1.74B
RXRXRecursion Pharmaceuticals Inc2.24B
UPBUpstream Bio Inc175.27M
ABCLAbCellera Biologics Inc3.90B
AMGNAMGEN Inc253.21B
REGNRegeneron Pharmaceuticals Inc99.23B
XNCRXencor Inc3.00B
ZYMEZymeworks BC Inc2.02B
SDGRSchrodinger Inc2.37B
AZNAstrazeneca plc287.66B

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ARNOLD FRANCESDirectorOct 29 '26Sale16.1911,409184,733220,063Nov 04 04:05 PM
ARNOLD FRANCESDirectorOct 29 '26Proposed Sale16.1911,409184,733Oct 29 04:12 PM
ARNOLD FRANCESDirectorSep 02 '26Proposed Sale16.1632,210520,631Sep 02 04:20 PM
ARNOLD FRANCESDirectorSep 01 '26Proposed Sale16.001,00016,002Sep 01 04:27 PM
Nally MichaelChief Executive OfficerMar 04 '26Buy12.0020,000240,000572,707Mar 06 04:55 PM
Grous BethChief People OfficerMar 02 '26Buy16.003004,800300Mar 02 06:05 PM
Silvers JasonPresident & CFOMar 02 '26Buy16.002,00032,0001,000Mar 02 05:54 PM
AFEYAN NOUBARDirectorMar 02 '26Buy16.004,687,50075,000,00015,264,724Mar 02 05:52 PM
Mendillo Jane LDirectorMar 02 '26Buy16.001,50024,0001,500Mar 02 05:47 PM
AFEYAN NOUBARDirectorMar 02 '26Buy16.004,687,50075,000,00015,264,724Mar 02 05:42 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
ARKGARK Genomic Revolution ETFAUM: 1.97B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
JTEKJPMorgan U.S. Tech Leaders ETFAUM: 4.15B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 18

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-06-0.520-0.508-6.315.306
2026Q12026-05-07-1.070-0.508-0.5407.225.285
2025Q42026-02-25-0.780--3.31--
2026Q3---0.557--7.756
2026Q4---0.583--7.656
2027Q1---0.547--2.003
2027Q2---0.533--2.753
2027Q3---0.517--3.253
2027Q4---0.523--3.923

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-4.545--7.57031.90-
2026FY--2.278--29.68
2027FY--2.295--23.83
2028FY--1.783--92.23
2029FY--2.975--22.50
2030FY--2.625--163.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-205007.755.0010.00
2026Q3S2026-09-075217.755.0010.00
2026Q3S2026-08-065217.765.0010.00
2026Q3S2026-05-075006.250.0010.00
2026Q3S2026-04-105006.250.0010.00
2026Q3S2026-03-234006.250.0010.00
2026Q3R2026-05-07100-0.48-0.48-0.48
2026Q3R2026-03-23100-0.48-0.48-0.48
2026Q3E2026-10-31600-0.56-0.67-0.44
2026Q3E2026-10-20610-0.56-0.67-0.44
2026Q3E2026-08-17614-0.56-0.67-0.44
2026Q3E2026-08-06604-0.56-0.67-0.47
2026Q3E2026-07-28600-0.54-0.67-0.47
2026Q3E2026-07-21601-0.54-0.67-0.47

Estimate history

EPS, annual-1.677-1.958
Period20242025
EPS, quarterly-1.616-1.939-0.54-0.524
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Sales, annual20.45931.893
Period20242025
Sales, quarterly8.81810.137.2246.314
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Shares, annual127.45127.45128.269
Period20242025MRQ
Shares, quarterly32.97733.022128.192128.269
PeriodQ1 '25Q2 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue6.3131.8920.46
Cost of Goods Sold Incl. D&A3.2213.1815.35
Gross Profit3.0918.715.11
Selling, General and Administrative Excl. Other74.70253.78202.05
Research and Development61.12211.63160.31
Other Operating Expense0.000.000.00
Operating Income-71.61-235.06-196.94
Interest Expense0.151.142.12
Unusual Expense0.000.110.15
Net Income Before Taxes-67.20-222.80-181.17
Income Taxes0.050.160.21
Consolidated Net Income-67.25-222.97-181.38
Net Income From Continuing Operations-67.25-203.15-173.77
Net Income-67.25-249.52-213.78
EPS (Recurring)-0.52-1.96-1.68
EPS (Basic, Before Extraordinaries)-0.52-1.96-1.68
EPS (Diluted)-0.52-1.96-1.68
EBITDA-68.39-221.89-181.59
Non-Operating Income (Expense)4.5713.5118.04
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense6.5116.2615.38
Gross Margin-58.6824.98
Operating Margin--737.04-962.60
Net Margin--782.38-1,044.90
Shares Outstanding128.27127.45127.45
Market Capitalization1,768.691,768.69-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Total Revenue6.317.2210.138.82
Cost of Goods Sold Incl. D&A3.223.273.323.41
Gross Profit3.093.956.815.40
Selling, General and Administrative Excl. Other74.7068.0666.9653.56
Research and Development61.1254.5656.4543.43
Other Operating Expense0.000.000.000.00
Operating Income-71.61-64.11-60.15-48.15
Interest Expense0.150.180.310.37
Unusual Expense0.000.360.000.00
Net Income Before Taxes-67.20-61.69-56.70-44.26
Income Taxes0.050.030.040.06
Consolidated Net Income-67.25-61.71-56.74-44.31
Net Income From Continuing Operations-67.25-61.45-52.43-41.69
Net Income-67.25-69.19-64.02-53.28
EPS (Recurring)-0.52-0.54-1.94-1.62
EPS (Basic, Before Extraordinaries)-0.52-0.54-1.94-1.62
EPS (Diluted)-0.52-0.54-1.94-1.62
EBITDA-68.39-60.84-56.83-44.74
Non-Operating Income (Expense)4.572.973.764.26
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense6.515.054.333.75
Gross Margin48.9454.6967.2161.28
Operating Margin-1,134.21-887.49-593.78-546.09
Net Margin-1,065.17-957.85-632.00-604.18
Shares Outstanding128.27128.1933.0232.98
Market Capitalization1,768.691,593.121,466.95-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments221.84395.05
Short Term Receivables0.000.31
Inventories0.000.00
Other Current Assets12.5312.13
Total Current Assets234.37407.49
Net Property, Plant & Equipment89.01101.07
Total Investments and Advances4.054.10
Deferred Tax Assets16.8018.59
Other Assets2.765.60
Total Assets346.98536.85
Short Term Debt Incl. Current Port. of LT Debt15.0116.72
Accounts Payable3.845.67
Other Current Liabilities63.3664.24
Total Current Liabilities82.2086.63
Long Term Debt53.5260.26
Provision for Risks Charges0.000.00
Deferred Tax Liabilities16.8018.59
Other Liabilities5.8316.61
Total Liabilities158.35182.09
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value811.83789.85
Common Equity-615.97-434.52
Total Shareholders Equity195.86355.33
Accumulated Minority Interest-7.23-0.57
Total Equity188.63354.76
Total Liabilities & Stockholders Equity346.98536.85
Book Value Per Share-4.83-3.41
Tangible Book Value Per Share-4.83-3.41
Full-Time Employees312-
Price to Book Ratio3.88-
Return on Assets-45.97-
Return on Equity-73.71-
Return on Invested Capital-81.46-41.81
Quick Ratio2.854.70
Current Ratio2.854.70

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-67.25-222.97-181.38
Depreciation3.2213.1815.35
Other Funds (Non Cash)10.5423.7820.17
Funds from Operations-53.49-186.00-145.87
Extraordinary Item0.000.000.00
Changes in Working Capital-4.46-14.6228.12
Cash from Operating Activities-57.94-200.62-117.75
Capital Expenditures-0.93-3.51-3.45
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.0013.155.01
Purchase or Sale of Investments34.24120.28-54.29
Purchase of Investments-0.61-164.73-282.98
Sale Or Maturity of Investments34.85285.01228.69
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities33.31129.92-52.73
Cash Dividends Paid0.000.000.00
Change in Capital Stock0.4123.0797.45
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock0.4123.0797.45
Proceedsfrom Stock Options0.0021.9796.32
Issuance or Reduction of Debt, Net-0.99-8.16-11.12
Change in Long Term Debt-0.99-8.16-11.12
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt-0.99-8.16-11.12
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities-0.5814.9186.33
Net Change in Cash-25.21-55.79-84.15
Free Cash Flow-58.88-204.13-121.20
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Cash & Short Term Investments457.42516.64--
Short Term Receivables0.000.00--
Inventories0.000.00--
Other Current Assets12.8418.75--
Total Current Assets470.25535.39--
Net Property, Plant & Equipment82.3885.60--
Total Investments and Advances4.030.00--
Other Assets5.024.75--
Total Assets561.69625.74--
Short Term Debt Incl. Current Port. of LT Debt13.6214.26--
Accounts Payable5.657.62--
Other Current Liabilities37.3636.51--
Total Current Liabilities56.6458.39--
Long Term Debt49.0151.31--
Provision for Risks Charges0.000.00--
Other Liabilities0.001.24--
Total Liabilities105.64110.94--
Non-Equity Reserves0.000.00--
Preferred Stock - Carrying Value0.000.00--
Common Equity456.05514.80--
Total Shareholders Equity456.05514.80--
Accumulated Minority Interest0.000.00--
Total Equity456.05514.80--
Total Liabilities & Stockholders Equity561.69625.74--
Book Value Per Share3.564.02--
Tangible Book Value Per Share3.564.02--
Price to Book Ratio3.88---
Return on Invested Capital-13.32-10.85--
Quick Ratio8.309.17--
Current Ratio8.309.17--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Net Income-67.25-61.71-56.74-44.31
Depreciation3.223.273.323.41
Other Funds (Non Cash)10.548.716.035.16
Funds from Operations-53.49-49.73-47.39-35.74
Extraordinary Item0.000.000.000.00
Changes in Working Capital-4.46-30.65-1.36-17.44
Cash from Operating Activities-57.94-80.39-48.75-53.18
Capital Expenditures-0.93-3.78-0.15-0.75
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.007.502.000.75
Purchase or Sale of Investments34.24-256.15-16.9176.28
Purchase of Investments-0.61-321.15-65.16-77.35
Sale Or Maturity of Investments34.8565.0048.24153.63
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities33.31-252.43-15.0776.28
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock0.41372.510.1522.46
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock0.41372.510.1522.46
Proceedsfrom Stock Options0.00369.29-0.0021.97
Issuance or Reduction of Debt, Net-0.99-1.11-2.42-2.65
Change in Long Term Debt-0.99-1.11-2.42-2.65
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt-0.99-1.11-2.42-2.65
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities-0.58371.39-2.2619.81
Net Change in Cash-25.2138.57-66.0842.92
Free Cash Flow-58.88-84.17-48.91-53.93

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.45%9.1M55.2M1.17M
2026-10-1516.18%8.9M55.2M1.08M
2026-09-3013.43%7.4M55.2M1.02M
2026-09-1513.00%7.2M55.2M1.04M
2026-08-3113.53%7.5M55.1M1.03M
2026-08-1413.22%7.3M55.1M834.56K
2026-07-3113.20%7.3M55.1M805.92K
2026-07-1512.69%7.0M55.1M784.57K
2026-06-3010.75%5.9M55.1M714.31K
2026-06-158.26%4.5M55.1M536.45K
2026-05-297.48%4.1M54.6M530.44K
2026-05-156.32%3.5M54.6M580.86K
2026-04-305.30%3.2M59.9M622.94K
2026-04-153.49%2.1M59.6M719.71K
2026-03-31-1.4M-877.46K
2026-03-13-0.9M-1.43M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.509.0013.500.000.0000.000.000.991-0.0170.001
call5.006.6011.000.0012.6810.000.000.956-0.0540.002
call7.504.108.503.508.3391.000.000.905-0.0750.004
call10.001.706.000.005.7270.000.000.847-0.0650.005
call12.501.301.502.001.2023010.000.706-0.0450.007
call15.000.250.400.401.1001,5311.000.298-0.0460.007
call17.500.050.450.071.1793300.000.093-0.0230.003
call20.000.000.250.051.6011080.000.073-0.0270.003
call22.500.000.250.001.9500.000.000.063-0.0290.003
call25.000.000.250.052.2482540.000.056-0.0300.002
put2.500.000.050.005.4160.000.00-0.009-0.0150.001
put5.000.000.250.004.8030.000.00-0.044-0.0530.002
put7.500.000.450.113.6984.004.00-0.095-0.0740.004
put10.000.004.400.152.27726.004.00-0.153-0.0640.005
put12.500.300.450.271.0682270.00-0.294-0.0440.007
put15.001.701.902.101.03723.000.00-0.702-0.0440.007
put17.501.505.902.503.77015.000.00-0.907-0.0220.003
put20.004.008.500.004.5130.000.00-0.927-0.0240.003
put22.506.5011.000.005.0180.000.00-0.937-0.0260.003
put25.009.0013.500.005.4440.000.00-0.944-0.0280.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13GSEC
2026-11-044Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-29144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-268-KCurrent report2026-08-25SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13GSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-03-123Initial statement of beneficial ownership of securities2026-03-02SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000184.73K1
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03150.30M600
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Flagship Pioneering, LLC48.89%
FMR LLC5.60%
Capital World Investors3.29%
BRAIDWELL LP2.56%
PRICE T ROWE ASSOCIATES INC /MD/1.68%
NORGES BANK1.63%
ARCH Venture Management, LLC1.52%
BANQUE PICTET & CIE SA1.38%
HARBOURVEST PARTNERS LLC1.34%
BlackRock, Inc.1.29%

Funds

Fund% owned
SMALLCAP World Fund Inc2.93%
Fidelity Growth Company Fund1.70%
ARK Genomic Revolution ETF0.97%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.64%
Fidelity Growth Company K6 Fund0.54%
iShares Russell 2000 ETF0.48%
JPMorgan Small Cap Growth Fund0.45%
Fidelity Series Growth Company Fund0.43%
ARK Venture Fund0.32%
T. Rowe Price Health Sciences Fund, Inc.0.25%

OakChart. GENB. Cached 15 minutes.